Immunosuppressant Management in Renal Transplant Patients with COVID-19

The coronavirus disease 2019 (COVID-19) pandemic poses a special risk for both immunosuppressed patients, especially transplant recipients. Although the knowledge about this infection is growing, many uncertainties remain, particularly regarding the kidney. Kidney transplant recipients (KDRs) should...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadian, Elham, Zununi Vahed, Sepideh, Mammadova, Shakar, Abediazar, Sima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531766/
https://www.ncbi.nlm.nih.gov/pubmed/34692845
http://dx.doi.org/10.1155/2021/9318725
_version_ 1784586933703278592
author Ahmadian, Elham
Zununi Vahed, Sepideh
Mammadova, Shakar
Abediazar, Sima
author_facet Ahmadian, Elham
Zununi Vahed, Sepideh
Mammadova, Shakar
Abediazar, Sima
author_sort Ahmadian, Elham
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic poses a special risk for both immunosuppressed patients, especially transplant recipients. Although the knowledge about this infection is growing, many uncertainties remain, particularly regarding the kidney. Kidney transplant recipients (KDRs) should be considered immunocompromised hosts since a potential risk for infection, comorbidity, and immunosuppression exposure exists. Additionally, the management of immunosuppressive agents in KDRs remains challenging. Potential drug interactions with immunosuppressive treatment escalated the risk of unwanted side effects. In this review, we aimed to attain an augmented awareness and improved management immunosuppressant for COVID-19 KDRs.
format Online
Article
Text
id pubmed-8531766
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85317662021-10-23 Immunosuppressant Management in Renal Transplant Patients with COVID-19 Ahmadian, Elham Zununi Vahed, Sepideh Mammadova, Shakar Abediazar, Sima Biomed Res Int Review Article The coronavirus disease 2019 (COVID-19) pandemic poses a special risk for both immunosuppressed patients, especially transplant recipients. Although the knowledge about this infection is growing, many uncertainties remain, particularly regarding the kidney. Kidney transplant recipients (KDRs) should be considered immunocompromised hosts since a potential risk for infection, comorbidity, and immunosuppression exposure exists. Additionally, the management of immunosuppressive agents in KDRs remains challenging. Potential drug interactions with immunosuppressive treatment escalated the risk of unwanted side effects. In this review, we aimed to attain an augmented awareness and improved management immunosuppressant for COVID-19 KDRs. Hindawi 2021-10-14 /pmc/articles/PMC8531766/ /pubmed/34692845 http://dx.doi.org/10.1155/2021/9318725 Text en Copyright © 2021 Elham Ahmadian et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ahmadian, Elham
Zununi Vahed, Sepideh
Mammadova, Shakar
Abediazar, Sima
Immunosuppressant Management in Renal Transplant Patients with COVID-19
title Immunosuppressant Management in Renal Transplant Patients with COVID-19
title_full Immunosuppressant Management in Renal Transplant Patients with COVID-19
title_fullStr Immunosuppressant Management in Renal Transplant Patients with COVID-19
title_full_unstemmed Immunosuppressant Management in Renal Transplant Patients with COVID-19
title_short Immunosuppressant Management in Renal Transplant Patients with COVID-19
title_sort immunosuppressant management in renal transplant patients with covid-19
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531766/
https://www.ncbi.nlm.nih.gov/pubmed/34692845
http://dx.doi.org/10.1155/2021/9318725
work_keys_str_mv AT ahmadianelham immunosuppressantmanagementinrenaltransplantpatientswithcovid19
AT zununivahedsepideh immunosuppressantmanagementinrenaltransplantpatientswithcovid19
AT mammadovashakar immunosuppressantmanagementinrenaltransplantpatientswithcovid19
AT abediazarsima immunosuppressantmanagementinrenaltransplantpatientswithcovid19

Ejemplares similares